Lucid Diagnostics Q4 EPS $(0.23) Beats $(0.26) Estimate, Sales $1.04M Miss $1.05M Estimate
Portfolio Pulse from Happy Mohamed
Lucid Diagnostics (NASDAQ:LUCD) reported Q4 earnings with a per-share loss of $(0.23), surpassing the $(0.26) estimate. However, their sales of $1.04M fell slightly short of the $1.05M estimate. Despite the earnings beat, the loss per share has widened from $(0.15) a year ago, while sales have significantly increased from $112.00 thousand.
March 25, 2024 | 9:44 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Lucid Diagnostics reported a smaller-than-expected Q4 loss per share but missed slightly on sales estimates. Year-over-year, the loss per share increased, while sales saw a significant jump.
The mixed results with an earnings beat but a slight miss on sales could lead to neutral short-term stock price movement. The significant year-over-year sales increase is positive, but the widening loss may concern investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100